KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.90

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

Jean-Jacques Kiladjian, Uma Borate, Elisabetta Abruzzese, Valerio De Stefano, Tiejun Gong, Massimo Breccia, Francesca Palandri, Fabrizio Pane, Andrea Patriarca, Hakon Reikvam, Lindsay Rein, Abdulraheem Yacoub, Feng Zhou, Michael Stouffs, Albert Assad, Alessandro Maria Vannucchi

Oncologist 31(7) oyag201

PMID42179186
PMCIDPMC13257860
DOI10.1093/oncolo/oyag201
发表日期2026-05-25
入排依据:The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original results, but the primary and key secondary endpoints are proportion-based (spleen volume reduction, symptom score reduction) and are not time-to-event outcomes. No time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) is reported or mentioned.
摘要

摘要

BACKGROUND: Ruxolitinib (JAK1/JAK2 inhibitor) is indicated for adults with intermediate or high-risk myelofibrosis; however, a subset of patients may exhibit a suboptimal response due to persistent PI3K/AKT activation. The phase 3, randomized, double-blind, placebo-controlled LIMBER-304 study (NCT04551053) investigated the efficacy and safety of add-on parsaclisib (highly selective PI3Kδ inhibitor) in patients with myelofibrosis and suboptimal or declining response to stable ruxolitinib monotherapy. PATIENTS AND METHODS: Adults with primary or secondary myelofibrosis who received ruxolitinib with palpable spleen and Myelofibrosis Symptom Assessment Form (MFSAF) total symptom score (TSS) ≥10 were eligible. Primary end point was proportion of patients achieving ≥25% spleen volume reduction (SVR; baseline to week 24); key secondary end point was proportion of patients with ≥50% MFSAF-TSS reduction (baseline to week 24). RESULTS: In total, 90 patients received parsaclisib/ruxolitinib; 87 received placebo/ruxolitinib. At week 24, 16.7% of patients receiving parsaclisib/ruxolitinib achieved ≥25% SVR vs 9.7% for placebo/ruxolitinib; this difference was not statistically significant. By week 24, ≥50% reduction in MFSAF-TSS was observed in 17.1% of patients receiving parsaclisib/ruxolitinib vs 14.1% for placebo/ruxolitinib. Higher rates of infections (including cytomegalovirus) and gastrointestinal disorders were observed with parsaclisib/ruxolitinib. Grade ≥3 treatment-emergent adverse events occurred in 60.0% of patients receiving parsaclisib/ruxolitinib vs 42.5% with placebo/ruxolitinib. The study was terminated early based on efficacy findings. CONCLUSIONS: Study results suggested adding parsaclisib to stable-dose ruxolitinib was unlikely to offer clinically meaningful benefits. Further research is needed on the potential of JAK and PI3K inhibitor-based combination therapy for patients with myelofibrosis.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 3

Figure 3. Change in MFSAF TSSs from baseline and likelihood of achieving a ≥50% reduction from baseline in MFSAF TSS in patients with myelofibrosis. (A) Percentage change in MFSAF TSS from baseline to week 24 (individual patient data; n = 117). Dotted line represents a 50% decrease in MFSAF TSS from baseline. (B) Median percentage change in MFSAF TSS from baseline. (C) Kaplan-Meier estimates of time to first ≥50% reduction in MFSAF TSS from baseline. Hashtags indicate patients with >100% percent change in MFSAF TSS from baseline. Tick marks indicate censored data. MFSAF, Myelofibrosis Symptom Assessment Form; TSS, total symptom score.

C

time to first ≥50% reduction in MFSAF TSS

Figure 3 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Change in spleen volume in patients with myelofibrosis. Percentage change in spleen volume from baseline to week 24 (individual patient data; n = 121). The dotted line represents a 25% decrease in spleen volume from baseline.
非 KM Figure
Figure 2Figure 2. Median change in spleen volume and spleen length in patients with myelofibrosis. Median percentage change from baseline in (A) spleen volume and (B) spleen length at all time points evaluated up to week 24. Error bars represent the interquartile range.
非 KM Figure
Figure 4Figure 4. Change in MFSAF score from baseline for individual symptoms. Median percentage change in MFSAF scores from baseline to week 24 for each of the individual symptoms assessed. MFSAF, Myelofibrosis Symptom Assessment Form.
非 KM Figure